Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.
Henrikas VaitkeviciusR Eugene RamsayChrista B SwisherAatif M HusainAlex AimettiMaciej GasiorPublished in: Epilepsia (2022)
IV ganaxolone achieved rapid and durable seizure control in patients with RSE, and showed acceptable safety and tolerability.